Abstract
Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are infrequent autoimmune cholestatic liver diseases, that disproportionate to their incidence and prevalence, remain very important causes of morbidity and mortality for patients with liver disease. Mechanistic insights spanning genetic risks and biological pathways to liver injury and fibrosis have led to a renewed interest in developing therapies beyond ursodeoxycholic acid that are aimed at both slowing disease course and improving quality of life. International cohort studies have facilitated a much greater understanding of disease heterogeneity, and in so doing highlight the opportunity to provide patients with a more individualized assessment of their risk of progressive liver disease, based on clinical, laboratory, or imaging findings. This has led to a new approach to patient care that focuses on risk stratification (both high and low risk); and furthermore allows such stratification tools to help identify patient subgroups at greatest potential benefit from inclusion in clinical trials. In this article, we review the applicability and validity of risk stratification in autoimmune cholestatic liver disease, highlighting strengths and weaknesses of current and emergent approaches. (Hepatology 2016;63:644–659)
Highlights
Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are infrequent autoimmune cholestatic liver diseases, that disproportionate to their incidence and prevalence, remain very important causes of morbidity and mortality for patients with liver disease
Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are chronic autoimmune cholestatic liver diseases, for which clinical outcome is largely dictated by development of cirrhosis, portal hypertension (PH), and variable predisposition to malignancy.[1,2,3,4]
PBC-Specific Anti-Nuclear Antibodies Unlike anti-mitochondrial antibody (AMA), which holds no prognostic value,[8,9,28] there exist several anti-nuclear antibody (ANA) subtypes that may associate with adverse clinical outcome in PBC
Summary
The full appreciation of the breadth of PBC as a disease has evolved as awareness has risen, given widespread access to anti-mitochondrial antibody (AMA) testing, reactivity of which in the presence of cholestasis facilitates robust and timely patient identification without need for histological confirmation.[6,7] PBC is increasingly identified at an earlier precirrhotic stage,[8] and wellconducted multicenter cohort studies have aided in the recognition of variant presentations (Table 2), including male patients and women age 1 year).[18,21]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
